Clinical Reviews in Bone and Mineral Metabolism

, Volume 4, Issue 4, pp 259–268 | Cite as

Parathyroid hormone and bone biomechanics

Article

Abstract

Parathyroid hormone (PTH) treatment, either in the form of teriparatide or recombinant human PTH(1–34), reduces the fracture risk of osteoporotic women by enhancing both structural and material biomechanical properties. Cortical bone thickness and cross-sectional moment of inertia increase because of new bone formation on periosteal and endocortical surfaces. Intracortical porosity is increased yet preferential localization near the endocortical surface limits any negative biomechanical effects. Greater trabecular bone volume results from a positive basic multicellular unit bone balance and renewed modeling. Initial increases in trabecular thickness are eventually reduced as a result of trabecular tunneling, increasing trabecular number, and connectivity. These geometrical and architectural alterations are the predominant mechanism by which PTH increases structural strength, stiffness, and energy absorption. PTH also positively alters material-level strength, modulus, and toughness. These changes are counterintuitive based on known effects of decreasing average tissue mineralization and increasing tissue heterogeneity. This combination of enhanced structural and material biomechanical properties makes PTH an effective treatment for reducing fracture risk despite smaller gains in bone mineral density compared to other osteoporosis agents.

Key Words

Teriparatide mechanical properties bone geometry trabecular architecture 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burr DB, Turner CH 2003 Biomechanics of bbone. In: Favus M (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. American Society for Bone and Mineral Research, Washington DC, pp 58–64.Google Scholar
  2. 2.
    Turner CH, Burr DB. 1993 Basic biomechanical measurements of bone: a tutorial. Bone 14:595–608.PubMedCrossRefGoogle Scholar
  3. 3.
    Currey JD. 2004 Tensile yield in compact bone is determined by strain, post-yield behavior by mineral content. J Biomech 37:549–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Black DM, Greenspan SL, Ensrud KE et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215.PubMedCrossRefGoogle Scholar
  5. 5.
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226.PubMedCrossRefGoogle Scholar
  6. 6.
    Dempster DW, Cosman F, Kurland ES et al. 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853.PubMedCrossRefGoogle Scholar
  7. 7.
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. 2003 Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941.PubMedCrossRefGoogle Scholar
  8. 8.
    Arlot M, Meunier PJ, Boivin G et al. 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253.PubMedCrossRefGoogle Scholar
  9. 9.
    Burr D, Hirano T, Turner C, Hotchkiss C, Brommage R, Hock J. 2001 Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157–165.PubMedCrossRefGoogle Scholar
  10. 10.
    Sato M, Westmore M, Ma YL et al. 2004 Teriparatide [PTH(1–34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623–629.PubMedCrossRefGoogle Scholar
  11. 11.
    Hirano T, Burr DB, Cain RL, Hock JM. 2000 Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1–34). Calcif Tissue Int 66:456–460.PubMedCrossRefGoogle Scholar
  12. 12.
    Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. 2001 Effects of human parathyroid hormone (1–34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28:538–547.PubMedCrossRefGoogle Scholar
  13. 13.
    Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM. 1999 Anabolic effects of human biosynthetic parathyroid hormone fragment (1–34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14:536–545.PubMedCrossRefGoogle Scholar
  14. 14.
    Jerome CP, Johnson CS, Vafai HT et al. 1999 Effect of treatment for 6 months with human parathyroid hormone (I–34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25:301–309.PubMedCrossRefGoogle Scholar
  15. 15.
    Uusi-Rasi K, Semanick LM, Zanchetta JR et al. 2005 Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958PubMedCrossRefGoogle Scholar
  16. 16.
    Zanchetta JR, Bogado CE, Ferretti JL et al. 2003 Effects of teriparatide [recombinant human parathyroid hormone (1–34] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543.PubMedCrossRefGoogle Scholar
  17. 17.
    Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH, 2000 Histomorphometric evidence for increased bone turnover without change in cortical thicness or porosity after 2 years of cyclical hPTH(1–34) therapy in women with severe osteoporosis. Bone 27:311–318.PubMedCrossRefGoogle Scholar
  18. 18.
    Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF. 1996 Effects of intermittent hPTH(1–34) alone and in combination with 1,25(OH)2 D3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11:600–613.PubMedGoogle Scholar
  19. 19.
    Martin RB, Burr DB, Sharkey NA. 1998. Skeletal Tissue Mechanics. Springer, New York.Google Scholar
  20. 20.
    Pead MJ, Skerry TM, Lanyon LE. 1988 Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J Bone Miner Res 3:647–656.PubMedGoogle Scholar
  21. 21.
    Hodsman AB, Steer BM. 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancerllous surfaces. Bone 14:523–527.PubMedCrossRefGoogle Scholar
  22. 22.
    Dobnig H, Turner RT. 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632–3638.PubMedCrossRefGoogle Scholar
  23. 23.
    Burr DB. 2005 Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep 3:19–24.PubMedGoogle Scholar
  24. 24.
    van der Linden JC, Homminga J, Verhaar JA, Weinans H. 2001. Mecanical consequences of bone loss in cancellous bone. J Bone Miner Res 16:457–465.PubMedCrossRefGoogle Scholar
  25. 25.
    Frost HM. 2004. The Utah Paradigm of Skeletal Physiology. vol. I. International Society of Musculoskeleted and Neuronal Interactions. GreeceGoogle Scholar
  26. 26.
    Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. 2001 Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis) Bone 28:150–159.PubMedCrossRefGoogle Scholar
  27. 27.
    Ulrich D, van Rietbergen B, Laib A, Ruegsegger P, 1999 The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 25:55–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Guo XE, Kim CH. 2002 Mechanical consequences of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 30:404–411.PubMedCrossRefGoogle Scholar
  29. 29.
    Pistoia W, van Rietbergen B, Ruegsegger P. 2003 Mechanical consequences of different scenarios for simulated bone atrophy and recovery in the distal radius. Bone 33:937–945.PubMedCrossRefGoogle Scholar
  30. 30.
    Sato M, Westmore M, Clendenon J, et al. 2000 Threedimension modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 11:871–880.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang L, Takahashi HE, Inoue J et al. 1997 Effects of intermittent administration of low dose human PTH(1–34) on cancellous and cortical bone of lumbar vertebral bodies in adult beagles. Bone 21:501–506.PubMedCrossRefGoogle Scholar
  32. 32.
    Kinney JH, Ladd AJ. 1998 The relationship between threedimensional connectivity and the elastic properties of trabecular bone. J Bone Miner Res 13:839–845.PubMedCrossRefGoogle Scholar
  33. 33.
    Goldstein SA, Goulet R, McCubbrey D. 1993 Measurement and significance of three-dimensional architecture to the mechanical integrity of trabecular bone. Calcif Tissue Int 53(Suppl 1):S127-S132: discussion S132–S133.PubMedCrossRefGoogle Scholar
  34. 34.
    Kabel J, Odgaard A, van Rietbergen B, Huiskes R. 1999 Connectivity and the elastic properties of cancellous bone. Bone 24:115–120.PubMedCrossRefGoogle Scholar
  35. 35.
    Compston JE. 1994 Connectivity of cancellous bone: assessment and mechanical implications. Bone 15:463–466.PubMedCrossRefGoogle Scholar
  36. 36.
    Keaveny TM. 2001. Strength of trabecular bone. In: Cowin S (ed.) Bone mechanics handbook. Second ed. CRC Press. Boca Raton.Google Scholar
  37. 37.
    Miller Z, Fuchs MB. 2005 Effect of trabecular curvature on the stiffness of trabecular bone. J Biomech 38:1855–1864.PubMedCrossRefGoogle Scholar
  38. 38.
    Meng XW, Liang XG, Birchman R et al. 1996 Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 11:421–429.PubMedCrossRefGoogle Scholar
  39. 39.
    Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL. 2003 Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1–34) for 18 months. J Bone Miner Res 18:769–775.PubMedCrossRefGoogle Scholar
  40. 40.
    Misof BM, Roschger P, Cosman F et al 2003 Effects of intermittent parathyroid hormone administration on bone minerlization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156.PubMedCrossRefGoogle Scholar
  41. 41.
    Burr DB, Schaffler MB, Frederickson RG 1988 Composition of the cement line and its possible mechanical role as a local interface in human compact bone. J Biomech 21:939–945.PubMedCrossRefGoogle Scholar
  42. 42.
    Vashishth D, Tanner KE, Bonfield W. 2003 Experiemntal validation of a microcracking-based toughening mechanism for cortical bone. J Biomech 36:121–124.PubMedCrossRefGoogle Scholar
  43. 43.
    O'Brien FJ, Taylor D, Lee TC. 2003 Microcrack accumulation at different intervals during fatigue testing of compact bone. J Biomech 36:973–980.PubMedCrossRefGoogle Scholar
  44. 44.
    Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM 2000 Six-month daily administration of parathryroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathryoid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathryoid hormine 893. J Bone Miner Res 15:1517–1525PubMedCrossRefGoogle Scholar
  45. 45.
    Ejersted C, Andreassen TT, Hauge EM, Melsen F, Oxlund H. 1995 Parathyroid hormone (1–34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17:507–511.PubMedCrossRefGoogle Scholar
  46. 46.
    Sato M, Zeng GQ, Turner CH. 1997 Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138:4330–4337.PubMedCrossRefGoogle Scholar
  47. 47.
    Sato M, Vahle J, Schmidt A et al. 2002 Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143:3230–3242.PubMedCrossRefGoogle Scholar
  48. 48.
    Currey JD. 2002 Bones: Structure and Mechanics. Princeton University Press. Princeton.Google Scholar
  49. 49.
    Marotti G, Favia A, Zallone AZ. 1972 Quantitative analysis on the rate of secondary bone mineralization. Calcif Tissue Res 10:67–81.PubMedCrossRefGoogle Scholar
  50. 50.
    Fuchs R, Allen M, Ruppel M, Miler L, Burr D. 2005 How long does secondary mineralization of osteonal bone take? J Bone Miner Res 20(Supp 1):M047.Google Scholar
  51. 51.
    van der Linden JC, Birkenhager-Frenkel DH, Verhaar JA. Weinans H. 2001. Trabecular bone's mechanical properties are affected by its non-uniform mineral distribution. J Biomech 34:1573–1580.PubMedCrossRefGoogle Scholar
  52. 52.
    Black DM, Bilezikian Jp, Ensrud KE et al. 2005 One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  1. 1.Department of Anatomy and Cell BiologyIndiana University School of MedicineIndianapolis
  2. 2.Department of Orthopaedic SurgeryIndiana University School of MedicineIndianapolis
  3. 3.Biomedical Engineering ProgramIndiana University-Purdue UniversityIndianapolis

Personalised recommendations